These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 16971761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [Abstract] [Full Text] [Related]

  • 3. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J, Cristiano E.
    Medicina (B Aires); 2001 Jul; 61(4):470-80. PubMed ID: 11563177
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P.
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W, Erasmus LP, Feneberg W, Straube A.
    Neurology; 2006 Jan 24; 66(2):275-7. PubMed ID: 16434675
    [Abstract] [Full Text] [Related]

  • 8. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J.
    Curr Med Res Opin; 2007 Jun 24; 23(6):1209-15. PubMed ID: 17559722
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Patients' views of interferon therapy in MS.
    Burgess M.
    Prof Nurse; 1998 Jun 24; 13(9):588-92. PubMed ID: 9782975
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R, Agarwal S, Borton L, Oneacre K, Lopez-Bresnahan MV.
    Adv Ther; 2011 Sep 24; 28(9):761-75. PubMed ID: 21870169
    [Abstract] [Full Text] [Related]

  • 15. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O, Stüve O, Archelos JJ, Hartung HP.
    J Neurol Sci; 2005 Jun 15; 233(1-2):173-7. PubMed ID: 15949504
    [Abstract] [Full Text] [Related]

  • 16. Lessons from randomised direct comparative trials.
    Achiron A, Fredrikson S.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.
    Value Health; 2004 Feb 01; 7(5):554-68. PubMed ID: 15367251
    [Abstract] [Full Text] [Related]

  • 18. [Drug therapy in multiple sclerosis].
    Le Page E, Edan G.
    Rev Prat; 2006 Jun 30; 56(12):1336-46. PubMed ID: 16948222
    [Abstract] [Full Text] [Related]

  • 19. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug 30; 19(108):160. PubMed ID: 20941852
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.